Abstract
Tirzepatide is the first ever once-weekly, injectable gastric inhibitory peptide/glucagon-like peptide1 (GIP/GLP-1) dual agonist approved by the European Medicines Agency for type2 diabetes. The efficacy and safety of tirzepatide have been evaluated in five global, randomized, double-blind or open-label, phase3 studies which enrolled over 7000 people living with type2 diabetes, across various stages of disease and with different characteristics at baseline. In this short commentary we report the salient data of the most recent trials on tirzepatide and GLP-1 receptor agonists from a clinical point of view, with the aim of highlighting similarities and mutual differences.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
